Abstract
The proportion of patients with cancers who develop
invasive fungal infections has increased dramatically over
the past few decades. Most of these infections are diagnosed
in patients with hematological malignancies, mainly
in patients with acute myeloid leukemia and those undergoing
allogeneic hematopoietic stem cell transplantation.
For years deoxycolate amphotericin B has been considered
the drug of choice for the treatment of invasive aspergillosis,
but it has been outclassed by its lipid formulations
and new triazoles (i.e. voriconazole), that produced
better response rates; nonetheless recovery from neutropenia
remains the most important factor influencing
outcome.
Lingua originale | English |
---|---|
pagine (da-a) | 5-8 |
Numero di pagine | 4 |
Rivista | Journal of Chemotherapy |
Volume | 23 |
Stato di pubblicazione | Pubblicato - 2011 |
Keywords
- Amphotericin B
- Antifungal Agents
- Aspergillosis
- Humans
- Neutropenia
- Pyrimidines
- Triazoles